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By the end of 1993 the nations of Belgium, Denmark,
Germany, Greece, Spain, France, Ireland, Italy, Luxembourg,
the Netherlands, Portugal, and the United Kingdom will have
completed the formation of a united trading block known as
the European Community (EC) . The formation of the EC allows
the member nations to remain competitive in a global market
place where many of their individual economies could not.
Foundations for the EC had been laid down over 30 years
ago with the treaty of Rome. The Treaty of Rome
established a customs union and required the elimination of
quantitative restrictions and all measures designed to
protect domestic markets from foreign competition.
However, internal and external forces like unemployment and
increased import competition perpetuated a protectionist
climate that effectively stifled the momentum towards
further integration. By the early
1980*
s it was apparent
that protectionist measures were ineffective. New momentum
toward further integration and cooperation among member
nations was growing.
A 1985 paper entitled "Completing the Internal
Market"
outlined a detailed plan for further European integration.
The paper included about 300 specific measures aimed at the
removal of all obstacles to the free movement of goods,
(1)
people, services and capital by December of 1992.
2
With
the ratification of these measures by the member nations, a
$4.6 trillion market will emerge operating on one set of
rules.
Within the total EC market, the medical device industry
accounted for approximately $7.4 billion in 1987, and this
segment continues to grow. Eighty percent of United States
medical device exports to the EC were received by five
member nations throughout 1987 and 1988 (Germany 25%,
France 16%, the UK 16%, the Netherlands 15%, and Italy
10%) . Including both exports and production by US
subsidiaries based in the EC, the United States holds over
50% of the EC market share for medical devices.
EC markets are most commonly regulated by EC
directives. These directives outline all aspects of the
manufacture, labeling, distribution and sale of goods in
the EC. The complexity of these guidelines varies with
each industry. It is section 14.1 of the EC Council
Directive of June 20 1990, Number L189/23 for the medical
device industry on which this study focuses. Section 14.1
outlines the labeling procedure for sterile medical device
packages. What is important about section 14.1 is its
inclusion of an expiration dating clause. This is a new
consideration for device manufacturers and most are
generating shelf life data for the first time. The
(2)
question is, are peelable device package seals effected by
age, and if so to what extent?
The paramount concern for the medical device industry
is the maintenance of sterility. The integrity of medical
device packaging can be compromised in a number of ways,
among them are
"pinholes"
(tiny voids in the packaging
materials or seal area large enough to allow the
penetration of micro organisms into the package) , damage to
the package, and ineffective seals. "According to the FDA
reports approximately 30% of all sterility related medical
device recalls in the fiscal year 1985 were for packaging
defects, usually involving seal
integrity."4
Typically
package seals are either manufactured improperly or damaged
through stresses incurred after the manufacturing process.
One of these manufacturing stresses may even be the
sterilization process itself, where gas sterilization is
employed. Sterilizing gas, most commonly ethylene oxide,
is forced with positive pressure into the package through a
micro-porous vent in the package. The gas is then drawn
out of the package by vacuum. In his article "Seal Fatigue
in ETO Sterilization", Carl Moarotta discusses the process
factors and material variables present in ETO sterilization
that can lead to partial or complete separation of package
seals. The process factors alone or in combination that
contribute to seal degradation are: temperature,
(3)
prehumidification, the rate of pressurization and
degassing, length of the cycle, and sterilization gas
mixture. The most important of these process factors is
the rate of pressurization and vacuum degassing. If the
rate of pressurization or vacuum degassing is too rapid,
stress will be exerted on the package seal area as the
sterilization gas is forced into or drawn out of the
package. The stress created can damage or completely
rupture package seals. This can be avoided through proper
design of the sterilization cycle to include gradual
pressurization and vacuum degassing. The material
variables include: chemical compatibility, sensitivity to
moisture, reactivity to sterilizer gasses, hot strength,
and plastic flow. In order to minimize seal fatigue these
variables are considered and materials are selected for
their compatibility with each other and the sterilization
cycle . For example, high porosity can be used to
compensate for poor hot strength by increasing gas flow and
reducing pressure induced stresses Likewise a high hot
strength adhesive can be used to compensate where a less
porous material is required. Through evaluation of the
sterilization procedure and material selection, the
phenomena of seal fatigue is
minimized.5
The polymer EVA (ethyl vinyl acetate) is commonly used
to create a peelable seal. EVA is ideal because it has
(4)
enough cohesive force to maintain package integrity while
remaining peelable, creating an easy opening feature for
the product user. The incorporation of easy open features
is more than a convenience. Features like peelable seals
help to minimize the potential for cross contamination that
could be introduced by difficult opening operations, the
use of tools or improper handling. EVA also has the added
advantages of peeling cleanly so that particulate
contamination is greatly reduced and is compatible with
both gas and radiation sterilization.
The Code of Federal Regulations or CFR under Title 21,
subpart G contains regulations pertaining to packaging and
labeling of medical devices. The CFR specifies in general
terms how device labeling is to be handled. Section (e)
of subpart G in the CFR, entitled "Labeling
Materials"
states, "Labeling materials issued for devices shall be
examined for identity and where applicable, the correct
expiration date, control number, storage instructions,
handling instructions, and additional processing
instructions. A record of such examination, including the
date and person performing the examination, shall be
maintained in the device history
record."
The key
phrase is "where applicable", the inclusion of an
expiration date is left to the discretion of the
manufacturer where there is no regulatory precedent.
(5)
In order to meet the regulations of the CFR, American
medical device manufacturers operate according to good
manufacturing practices or GMP's which are monitored by the
Food and Drug Administration (FDA) . The system focuses on
total quality assurance in the manufacture, handling and
packaging of products to insure the manufacture of a
reliable sterile device. Under the GMP system the quality
and reliability of a device is understood or implied. This
differs from the EC system where the directives for the
device industry call on the manufacturers to make specific
statements about the devices application limitations and
sterility. This European method is illustrated in section
14.1 of Council Directive of June 20 1990, No L 189/23, the
sterile device must be marked with:
- the method of sterilization,
- an indication permitting this package to be
recognized as such,
- the name and address of the manufacturer,
-
a description of the device,
- if the device is intended for clinical
investigations, the words: "exclusively for
clinical investigations",





- a declaration that the implantable device is
in sterile condition,
- the month and year of manufacture,
-
an indication of the time limit for
implanting the device
safely.7
Essentially what this means is that the EC is placing the
burden of liability for the device on the manufacturer. In
fact, most of this is not new, device manufacturers have
previously been providing the bulk of this information.
What is new about this EC Directive is the inclusion of a
shelf life by expiration dating for all device packaging
and its impact on the medical device industry. It is
uncommon for device manufacturers to include expiration
dates because they are not required by the CFR. Those
manufacturers interested in the European market are now in
the process of generating shelf life data for the first
time, as a consequence of the new EC regulations.
Real time aging studies would certainly offer the best
documentation for any expiration date claims made by device
manufacturers. However, considering the time required to
generate real time data, manufacturers are turning to
accelerated age studies to support expiration date claims.
The concept of accelerated aging was first used in the
chemical industry to explore the degradation of chemical
compounds and was later applied to the pharmaceutical
(7)
industry as a tool to predict the shelf life of drug
compounds. Accelerated aging works on the principle of
kinetics. As the temperature increases the rate of
chemical reactions increase. The rate of increase is
linear therefore a direct relationship between temperature
and the rate the chemical reactions can be established.
This concept is more thoroughly addressed under the "SAMPLE
PREPARATION"
section.
Overall, the formation of the EC is a positive
development for American device manufacturers marketing
their products in Europe. While short term, device
manufacturers are forced to meet the new EC directives, in
the long run they can look forward to more efficient




This study addresses the question of the effects of
accelerated aging on peelable medical device package
seals. The effects of aging on device seals is a
previously unexplored area. With the formation of the EC
and more specifically its requirement for expiration dating
the sterility of a device package, seal integrity over time
becomes an important consideration.
HYPOTHESIS : Post sterilization seal strength does not
degrade over time.
To test this hypothesis the seal area of device
packages that had been subjected to an accelerated aging
cycle were compared to a control group of new device
packages of the same size and style. The seal area of both
groups tested, i.e. new packages and aged packages, were
isolated by sealing the porous side of the package. A
burst tester was used to determine the seal strength of




The seal strength of a package can be evaluated in a number
of ways. Methods commonly employed are vacuum testing,
tensile testing and burst testing. However each test
method has its advantages and short comings.
VACUUM TESTING:
Vacuum testing uses a submersion chamber in which the
package is placed. Subsequently a vacuum is drawn on the
chamber causing the trapped air in the package to expand.
If the vacuum is increased, the seal area of the package
will eventually rupture. Vacuum testing has the advantage
of making the detection of pinholes easy. Pinholes are
voids in the package material or the seal area large enough
to allow the entry of micro organisms, compromising
sterility. Vacuum testing also has the advantage of
locating voids in the seal area of a package that would be
difficult or impossible to detect with manual inspection.
Vacuum testing is an excellent means to identify sealing
problems by showing where the weak or defective portion is
located so that equipment adjustments can be made. However
submersion of a package in order to vacuum test is not
practical when a material like paper or
TYVEKR
is used.
Air can escape through the porous material instead of
exerting force on the seal area confounding the results. A
second
(10)
problem is the saturation of the package material, i.e.
medical grade paper, when submerged. This reduces the
strength of the paper enough to create material failures
rather than the desired seal failure.
TENSILE TESTING:
Tensile testing consists of cutting standard width one
inch samples of the seal area from various locations of the
package. These samples are then tested for pull strength
on a tensile tester. The values may be averaged to
determine the seal strength of the package. Tensile
testing can be employed with a paper or TYVEK sided
pouch but is not an effective means of testing the entire
seal area intact. This may lead to inadvertent omission of
a poorly sealed area in the package. In addition tensile
testing is labor intensive and handling of samples
introduces a large potential for human error. The test
samples can be damaged during cutting procedures or when
placed in the jaws of the tensile tester. If the sample is
not properly aligned in the jaws of the tensile tester
inaccurate results are also likely to occur.
BURST TESTING:
Burst testing injects air into a sealed package at a
controlled rate. The backpressure developed inside the
package is measured by a sensitive gauge or sensor within
the burst test unit. Typically the burst test units hold
(11)
the highest internal pressure reading measured by the
sensor prior to seal failure giving the seal strength of
the package. Although burst testing can not detect
pinholes, it does have the advantage of testing the entire
seal area intact while maintaining dry test conditions
making it suitable for moisture sensitive package materials
like medical grade paper.
(12)
EQUIPMENT
Burst testing was the test method selected because the
seal area could be tested in its entirety, under dry
conditions (both requirements of the packages provided for
testing) . Modern Controls Inc. agreed to provide the burst




In the interest of isolating the seal area of the
packages and eliminating any potential variability in the
porosity of the package, the paper backing of the pouches
was sealed with 0.08 mm pressure sensitive case packing
tape. Special care was taken during this procedure to
insure that the seal area was not stressed. This
effectively eliminated the escape of air through the paper
side of the pouch. Sealing the porous side of the package
also allowed for a slower pressure increase rate. The
slower pressure increase rate decreased the likelihood of
"shocking" the package seals (a reduction of seal strength
brought about by rapid inflation of the package) .
The test packages and the accelerated aging cycle used
for the study came from ETHOX CORPORATION. The concept of
accelerated aging schemes applied to medical device
packaging is borrowed from the test methods used in the
pharmaceutical and chemical industries. The theory behind
it is based on using a thermodynamic temperature
coefficient. "A rule that was first formulated by Von't
Hoff states that a rise in temperature of 10C will
double the rate of a chemical reaction. This rule is
usually expressed as a Q10 value i.e., the
ratio of the
rate of reaction at two temperatures 10C apart. If the
(14)
rate of the reaction is doubled, then Q10
= 2. This is
also the most common approach used in the medical device
industry for conducting packaging studies. It is generally
extrapolated as indicated in the following example:
If QlO
= 2 and tne accelerated aging
temperature = 71C (160F) , or 55C
over ambient temperatures, then the aging
factor is 2r>,:}, or 45 times. Therefore, 52
weeks/45 = l.l week, or approximately 1 week
at 71C (160F) is equivalent to 1 year
at ambient temperature conditions."8
It is important to realize that the Q10
= 2 principle is
not linear and the Q10 value at higher temperatures
gradually drops off to a Q10
= 1 or lower. This is
recognized by the federal standards which set 71C as the
maximum temperature for accelerated testing of packaging
materials. Few device packages are composed of a single
material, therefore in order to simplify the equation and
make it more manageable, the Q10
= 2 principle also
assumes a single reaction rate for a package. In fact a
package composed of more than one material is likely to
have different reaction rates acting on the different
materials. This may lead to different modes of failure
that might not occur with real time aging studies.
Therefore it is important to realize individual reaction
rates occurring in a given package, and approximately
select a test temperature that will not create unrealistic
circumstances for that given package.
(15)
Environmental conditions should also be taken into
consideration in designing an appropriate accelerated aging
scheme. Both relative humidity (high and low) and low
temperatures have been shown to contribute to package
failure. Changes in humidity will cause fluctuations in
the moisture content of paper products effecting their
strength. Likewise plastic packaging' s material properties
are altered under cold conditions. Low temperatures can
reduce flexibility of films and under extreme conditions
make them brittle. Therefore a well thought out sequence
should include periods of high and low humidities as well
as a period of cold storage. Some or all of these
conditions will be encountered during distribution both
domestically and overseas.
The aged packages used in this study were exposed to
130F 70% RH for eight weeks, frozen to 0F for 24
hours, thawed to ambient temperature for an additional 24
hours, and then exposed to 130F @ less than 15% RH for
another eight weeks to achieve an equivalent to four years
real time as shown in the following calculation:
(16)
ACCELERATED TEMP. 130F = 54.4C
AMBIENT TEMP. 62F = 16.7C
54.4C - 16.7C = 37.7C
37.7C / 10 = 3.7
THE AGING FACTOR IS
23'7
OR 13 TIMES THE AMBIENT RATE.
52 WEEKS / 13 = 4 WEEKS.
THEREFORE: 4 WEEKS 130F IS EQUIVALENT TO 1 YEAR
AMBIENT TEMPERATURE CONDITIONS (62F) .
The packages were tested on the closed package tester
(provided with the burst test unit from Modern Controls
Inc.) which allowed for unsupported testing of the
package. Thus preventing the possibility of any undue
force being applied to the seal area of the specimen.
Both groups of packages tested were manufactured to
identical specifications. The packages were vented pouches
intended for ETO sterilization, with a clear film side for
identification of the product and EVA coated medical grade
paper on the opposite side (SEE fig. 1 for dimensions) .
(17)
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1. The inflation rate of 5 psi/min was selected and set on
the equipment. A slow inflation rate is used so that the
seal area was not
"shocked"
or weakened during the
preinflation of the test package.
2. Clear case sealing tape was applied to the paper side
of the pouch. Care was taken so that the seal area was not
damaged and only the porous areas were covered.
3 . A hole approximately 2mm in diameter was made in the
center of the film side of the pouch.
4 . An adhesive backed rubber septum (provided by MOCON for
use with the Skye burst test unit) was applied over the
hole in the film side of the pouch. NOTE: Care was taken
to be certain that the hole in the septum is centered over
the hole in the package to insure unrestricted air flow.
5. The needle of the closed package tester was inserted
into the hole in the septum.
6. The test cycle was initiated by depressing the start
button on the burst test unit.
7. The psi burst test value displayed on the burst test




The first column "sample #" indicates the number of the
sample tested. The second column "burst value
(PSI)"
indicates the internal package pressure at seal failure.
The third column "location" indicates where on the package
the seal failure occurred.
LOTUS 123 spreadsheet software was used to create the
data tables listing all samples tested in each population
(new and accelerated aged packages) and generate the
population mean, min, max, range and standard deviation.
The new package population had a mean burst value of
1.7 psi, with a 2.7 psi maximum value and a 1.0 psi minimum
value creating a range of 1.7 psi with a standard deviation
of 0.5. Seal failures on each package tested occurred
along one of the side package seals with 36% on the left
side seal and 64% on the right side seal.
The aged package population had a mean burst value of
0.9 psi, with a 1.6 psi maximum value and a
0.6 psi minimum
value creating a range of 1.0 psi with
a standard deviation
of 0.2. As with the new package population, the aged
package population seal failures occurred along one of the
side seals, 50% along the right and 50% along
the left.
(20)
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P/N 150 Four Pocket Instrument Holder































































































LEFT SEAL FAILURES 10 (36%)
RIGHT SEAL FAILURES 18 (64%)
(23)
DATA
ETHOX SURGI-KIT P/N 150 Four Pocket Instrument Holder
Accelerated Aged Packages:







































































LEFT SEAL FAILURES 10 (50%)
RIGHT SEAL FAILURES 10 (50%)
(24)
STATISTICAL ANALYSIS SUMMARY
The statistical analysis was performed on MINITAB
statistical software. Data was entered and manipulated
with the appropriate MINITAB commands to determine sample
size, mean, median, standard deviation, minimum, maximum
and quartiles one and three. A two sample T test with a
95% confidence interval was performed to test the validity
of the hypothesis "Post sterilization seal strength does
not degrade with time" with the null hypothesis "MU new =
MU aged". The T test generated a T value of 7.44 and a P
value of 0.0000 with 43 degrees of freedom. The 0.0000 P
value indicates 0 probability that the null hypothesis is








MTB > DESCRIBE Cl C2
N MEAN MEDIAN TRMEAN
SEMEAN
NEW 28 1.6750 1.6000 1.6615
0.0887
AGED 20 0.8900 0.9000 0.8667
0.0571
MIN MAX Ql Q3
NEW 1.0000 2 .7000 1.3000 1.8750
AGED 0.6000 1 .6000 0.7000 1.0000
MTB > TWOSAMPLE T Cl C2 ;
SUBO ALTE +1.
TWOSAMPLE T FOR NEW VS AGED
N MEAN STDEV
NEW 28 1.675 0.470







95 PCT CI FOR MU NEW - MU AGED: (0.572, 0.998)
TTEST MU NEW = MU AGED (VS GT) : T= 7.44 P=0.0000
DF= 43
(26)
POTENTIAL SOURCES OF ERROR
It important to consider the reliability of the data
and where potential sources of error lie. This conclusion
is based on a small sample population and although it
appears to support a conclusion, a much stronger statement
could be made with a larger test population.
The aging cycle used in this study may have had some
impact on the results through over drying the paper beyond
ambient conditions. Over drying should be considered as a
potential contributor to the reduced seal strength.
Other potential sources of error exist in how the
testing is performed. In order to generate comparable data
sample preparation and test procedures must be identical.
Equipment is another area that must be considered. For
instance, has the equipment been calibrated. Another
equipment consideration, has the equipment been set up and
operated properly.
(27)
RECOMMENDATIONS FOR FURTHER STUDY
It is possible to draw inaccurate conclusions about a
population with too small a sample. As a next step to
confirm this studies conclusions, this study could be
repeated with an increased sample size. The larger samples
would provide stronger data, lending greater statistical
validity to the conclusion that seal strength decreases
over time.
It should also be recognized that even though an
accelerated aging regime is designed to mimic the effects
of real time aging, stresses exerted on the package during
the accelerated aging cycle may produce a result that
differs from that observed with real time aging. Next
steps should include a study of real time aged packages vs
new packages to confirm the findings of this study.
One question that has come out of this study is the
progression of the degradation. to address this a next
step could be additional burst testing to
determine the
rate of seal degradation. New vs aged packages, aged to:
one year, two years, three years, four
years.
Variability of materials and the
impact of aging on
those materials could be addressed with additional burst
testing of aged
TYVEKR
vs aged medical grade paper to
determine if seal integrity can be optimized.
(28)
CONCLUSION
Based on the statistical analysis we see two distinct
populations indicating that accelerated aging has created a
reduction of seal strength. Looking at the average burst
strengths of new vs aged packages a 47% reduction in seal
strength was observed. This information is significant
because these packages have been thought of as static,
remaining unchanged over time. Here we see this is not the
case. These packages are dynamic and this could impact the
sterile barrier of a package. However this information
alone is of no value. The change must be put into
context. Is the seal strength of the aged packages
sufficient to maintain package integrity?
It is unreasonable to think that the loss of seal
strength has occurred all at once. More likely the loss of
seal strength is gradual. This is significant when we look
at the demands placed on the sterile barrier of the
package. Where do the greatest stresses to the package
occur? The sterilization process and the distribution
environment are where the greatest demands are placed on
the package.
The packaging of sterile
devices is performed under
conditions that keep the initial bioburden to a
minimum.
(29)
This in turn reduces the demands on the sterilization
cycle. For this reason sterilization is performed shortly
after the packing operation when the bioburden is at its
lowest. It is at this time that the seals are at their
optimum strength. Degradation due to aging will have no
impact at the time of sterilization. Distribution is also
likely to occur relatively early in the life of the package
The distribution cycle is the place where any product
is most susceptible to damage. The risk to the package in
distribution varies with the type of handling and how the
product is shipped. Manual handling and mixed shipments
will produce higher levels of stress to a package and are
common in the wholesale distribution of medical products.
Distribution from the manufacturer to the wholesaler and
the wholesaler to the end user will occur within a year for
most products. Assuming that the degradation of the seal
strength is linear, the impact of distribution at this
stage of the packages life is minimal given the
distribution packaging has been properly designed.
Package material selection probably has an impact on
the degradation of seal strength. The packages tested were
heat sealed pouches manufactured from an EVA zone coated
medical grade paper and
"plastic" film. The film side of
the pouch does not experience fluctuations in its material
properties due to humidity. The paper side of the pouch
(30)
was selected to provide the porosity required for ETO
sterilization. However paper is very susceptible to
changes in its material properties due to the humidity of
the surrounding environment and naturally dries with age.
This moisture loss of the paper probably contributed to
the reduction in seal strength.
A vented pouch manufactured with
TYVEKR
rather than
medical grade paper would provide the required porosity
without material fluctuations induced by environmental
factors. Seal strength does appear to degrade over time.
Therefore shelf life regulations for medical product
packaging is not an unreasonable regulation. This study
demonstrates that it is possible to quantify the loss in
strength and identify a point where the stresses placed on
the package may compromise the sterility of the
product.
Through proper material selection and testing packagers
can optimize the shelf life of a sterile product. With an
understanding of the package's
life cycle, the shelf life
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